This is an old revision of this page, as edited by SmackBot (talk | contribs) at 05:24, 17 December 2009 (remove Erik9bot category,outdated, tag and general fixes). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 05:24, 17 December 2009 by SmackBot (talk | contribs) (remove Erik9bot category,outdated, tag and general fixes)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) | This article does not cite any sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Tyloxapol" – news · newspapers · books · scholar · JSTOR (December 2009) (Learn how and when to remove this message) |
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.209.660  |
| Chemical and physical data | |
| Formula | (C15H21O(C2H4O)m)n |
| Molar mass | variable |
Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type. It is used as a surfactant to aid liquefaction and removal of mucopurulent (containing mucus and pus) bronchopulmonary secretions, administered by inhalation through a nebulizer or with a stream of oxygen. With intraperitoneal injection, tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins.
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |